Effect of combined therapy of human Wharton's jelly-derived mesenchymal stem cells from umbilical cord with sitagliptin in type 2 diabetic rats

Endocrine

Volumn 45, Issue 2, 2014, Pages 279-287

  Hu, Jianxia ^a   Wang, Fang ^a   Sun, Ruixia ^a   Wang, Zhongchao ^a   Yu, Xiaolong ^a   Wang, Li ^a   Gao, Hong ^a   Zhao, Wenjuan ^a   Yan, Shengli ^a   Wang, Yangang ^a  

^a QINGDAO UNIVERSITY   (China)

Author keywords

Human umbilical cord mesenchymal stem cells; Islet cells; Sitagliptin; Type 2 diabetes

Indexed keywords

C PEPTIDE; GLUCAGON; GLUCOSE; HEMOGLOBIN A1C; SITAGLIPTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL REGENERATION; CONTROLLED STUDY; DRUG EFFICACY; GLUCOSE BLOOD LEVEL; GRAFT REJECTION; HUMAN; HUMAN CELL; HYPERGLYCEMIA; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RAT; THERAPY EFFECT; WHARTON JELLY;

ANIMALS; C-PEPTIDE; CELL PROLIFERATION; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; GLUCAGON; HEMOGLOBIN A, GLYCOSYLATED; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN-SECRETING CELLS; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; PYRAZINES; RATS; RATS, WISTAR; STREPTOZOCIN; TREATMENT OUTCOME; TRIAZOLES; UMBILICAL CORD;

EID: 84896724104     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-013-9984-0     Document Type: Article

References (34)

1. H. King, R.E. Aubert, W.H. Herman, Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 21, 1414-1431 (1998)
2. E.A. Nyenwe, T.W. Jerkins, G.E. Umpierrez, A.E. Kitabchi, Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes. Metabolism 60, 1-23 (2011)
3. V. Volarevic, N. Arsenijevic, M.L. Lukic, M. Stojkovic, Concise review: mesenchymal stem cell treatment of the complications of diabetes mellitus. Stem Cells 29, 5-10 (2011)
4. H.K. Salem, C. Thiemermann, Mesenchymal stromal cells: current understanding and clinical status. Stem Cells 28, 585-596 (2010)
5. F.E. Ezquer, M.E. Ezquer, D.B. Parrau, D. Carpio, A.J. Yañez, P.A. Conget, Systemic administration of multipotent mesenchymal stromal cells reverts hyperglycemia and prevents nephropathy in type 1 diabetic mice. Biol. Blood. Marrow. Transplant. 14, 631-640 (2008)
6. R. Jiang, Z. Han, G. Zhuo, X. Qu, X. Li, X. Wang, Y. Shao, S. Yang, Z.C. Han, Transplantation of placenta-derived mesenchymal stem cells in type 2 diabetes: a pilot study. Fr. Med. 5, 94-100 (2011)
7. R. Abdi, P. Fiorina, C.N. Adra, M. Atkinson, M.H. Sayegh, Immunomodulation by mesenchymal stem cells: a potential therapeutic strategy for type 1 diabetes. Diabetes 57, 1759-1767 (2008)
8. Y.L. Si, Y.L. Zhao, H.J. Hao, X.B. Fu, W.D. Han, MSCs: biological characteristics, clinical applications and their outstanding concerns. Ageing. Res. Rev. 10, 93-103 (2011)
9. R. Anzalone, M. Lo Iacono, T. Loria, A. Di Stefano, P. Giannuzzi, F. Farina, G. La Rocca, Wharton's jelly mesenchymal stem cells as candidates for beta cells regeneration: extending the differentiative and immunomodulatory benefits of adult mesenchymal stem cells for the treatment of type 1 diabetes. Stem. Cell. Rev. 7, 342-363 (2011)
10. J.S. Nachnani, D.G. Bulchandani, A. Nookala, B. Herndon, A. Molteni, P. Pandya, R. Taylor, T. Quinn, L. Weide, L.M. Alba, Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas. Diabetologia 53, 153-159 (2010)
11. M. Monami, I. Iacomelli, N. Marchionni, E. Mannucci, Dipeptydil peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr. Metab. Cardiovasc. Dis. 20, 224-235 (2010)
12. A.V. Matveyenko, S. Dry, H.I. Cox, A. Moshtaghian, T. Gurlo, R. Galasso, A.E. Butler, P.C. Butler, Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin. Diabetes 58, 1604-1615 (2009)
13. Y. Moritoh, K. Takeuchi, T. Asakawa, O. Kataoka, H. Odaka, The dipeptidyl peptidase-4 inhibitor alogliptin in combination with pioglitazone improves glycemic control, lipid profiles, and increases pancreatic insulin content in ob/ob mice. Eur. J. Pharmacol. 14, 448-454 (2009)
14. M.J. Reed, K. Meszaros, L.J. Entes, M.D. Claypool, J.G. Pinkett, T.M. Gadbois, G.M. Reaven, A new rat model of type 2 diabetes: the fat-fed, streptozotocin-treated rat. Metabolism 49, 1390-1394 (2000)
15. M. Sioud, New insights into mesenchymal stromal cell-mediated T-cell suppression through galectins. Scand. J. Immunol. 73, 79-84 (2011)
16. S. Wild, G. Roglic, A. Green, R. Sicree, H. King, Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27, 1047-1053 (2004)
17. H. Yang, X. Jin, C.W. Kei Lam, S.K. Yan, Oxidative stress and diabetes mellitus. Clin. Chem. Lab. Med. 49, 1773-1782 (2011)
18. V.M. Victor, M. Rocha, R. Herance, A. Hernandez-Mijares, Oxidative stress and mitochondrial dysfunction in type 2 diabetes. Curr. Pharm. Des. 17, 3947-3958 (2011)
19. P. Jin, X. Zhang, Y. Wu, L. Li, Q. Yin, L. Zheng, H. Zhang, C. Sun, Streptozotocin-induced diabetic rat-derived bone marrow mesenchymal stem cells have impaired abilities in proliferation, paracrine, antiapoptosis, and myogenic differentiation. Transpl. Proc. 42, 2745-2752 (2010)
20. F. Ezquer, M. Ezquer, V. Simon, P. Conget, The antidiabetic effect of MSCs is not impaired by insulin prophylaxis and is not improved by a second dose of cells. PLoS ONE 6, e16566 (2011)
21. G.I. Bell, H.C. Broughton, K.D. Levac, D.A. Allan, A. Xenocostas, D.A. Hess, Transplanted human bone marrow progenitor subtypes stimulate endogenous islet regeneration and revascularization. Stem. Cells. Dev. 21, 97-109 (2012)
22. J.H. Ho, T.C. Tseng, W.H. Ma, W.K. Ong, Y.F. Chen, M.H. Chen, M.W. Lin, C.Y. Hong, O.K. Lee, Multiple intravenous transplantations of mesenchymal stem cells effectively restore long-term blood glucose homeostasis by hepatic engraftment and β-cell differentiation in streptozocin-induced diabetic mice. Cell Transpl. 21, 997-1009 (2012)
23. J.W. Lee, X. Fang, A. Krasnodembskaya, J.P. Howard, M.A. Matthay, Concise review: mesenchymal stem cells for acute lung injury: role of paracrine soluble factors. Stem Cells 29, 913-919 (2011)
24. R. Hass, A. Otte, Mesenchymal stem cells as all-round supporters in a normal and neoplastic microenvironment. Cell. Commun. Signal. 10, 26 (2012)
25. L. Wang, Y. Zhao, S. Shi, Interplay between mesenchymal stem cells and lymphocytes: implications for immunotherapy and tissue regeneration. J. Dent. Res. 91, 1003-1010 (2012)
26. P.J. Tsai, H.S. Wang, Y.M. Shyr, Z.C. Weng, L.C. Tai, J.F. Shyu, T.H. Chen, Transplantation of insulin-producing cells from umbilical cord mesenchymal stem cells for the treatment of streptozotocin-induced diabetic rats. J. Biomed. Sci. 19, 47 (2012)
27. E.J. Verspohl, Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. Pharmacol. Ther. 124, 113-138 (2009)
28. T. Kitamoto, M. Takemoto, M. Fujimoto, T. Ishikawa, S. Onishi, E. Okabe, R. Ishibashi, K. Kobayashi, H. Kawamura, K. Yokote, Sitagliptin successfully ameliorates glycemic control in werner syndrome with diabetes. Diabetes Care 35, e83 (2012)
29. J.E. Stevens, M. Horowitz, C.F. Deacon, M. Nauck, C.K. Rayner, K.L. Jones, The effects of sitagliptin on gastric emptying in healthy humans - a randomised, controlled study. Aliment. Pharmacol. Ther. 36, 379-390 (2012)
30. S.G. Chrysant, G.S. Chrysant, Clinical implications of cardiovascular preventing pleiotropic effects of dipeptidyl peptidase-4 inhibitors. Am. J. Cardiol. 109, 1681-1685 (2012)
31. B. Hocher, C. Reichetzeder, M.L. Alter, Renal and cardiac effects of DPP-4 Inhibitors - from preclinical development to clinical research. Kidney. Blood. Press. Res. 36, 65-84 (2012)
32. Y.T. Chiang, W. Ip, T. Jin, The role of the Wnt signaling pathway in incretin hormone production and function. Front. Physiol. 3, 273 (2012)
33. Y. Yamada, Diabetes mellitus and osteoporosis. Incretin as a coordinator of glucose and bone metabolism. Clin. Calcium. 22, 1353-1358 (2012)
34. S. Cernea, The role of incretin therapy at different stages of diabetes. Rev. Diabet. Stud. 8, 323-338 (2011)